1,241 filings
Page 3 of 63
6-K
v0wbdomt k79
27 Apr 23
Current report (foreign)
9:32am
SC TO-T/A
lygdcq
27 Apr 23
Third party tender offer statement (amended)
6:16am
SC TO-T/A
yz0f0lbrn2
26 Apr 23
Third party tender offer statement (amended)
6:16am
6-K
70d516xoxtug gpb2
24 Apr 23
Current report (foreign)
9:55am
6-K
btz6mmz2qqx6453f1lgc
11 Apr 23
Current report (foreign)
1:02pm
SC TO-T/A
aeg9le2
10 Apr 23
Third party tender offer statement (amended)
4:38pm
S-8
vrtvacqd 9julogp2h8m
30 Mar 23
Registration of securities for employees
1:36pm
SC TO-T
330nijyl
24 Mar 23
Third party tender offer statement
7:10am
6-K
5o59ea6t
23 Mar 23
Current report (foreign)
4:00pm
SC TO-C
kbidh2cj6gui9a4a7ao
17 Mar 23
Information about tender offer
4:16pm
6-K
v1bu9td
14 Mar 23
Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
12:05pm
SC TO-C
k82m38fx50j 2ykpf
13 Mar 23
Information about tender offer
4:15pm
S-8 POS
fdhj73ysg5nhiw2
13 Mar 23
Registration of securities for employees (post-effective amendment)
11:40am
6-K
zxy24czuc1dok0vd
13 Mar 23
Current report (foreign)
7:38am
6-K
vv0h zepwhx
6 Mar 23
Current report (foreign)
11:57am
6-K
ij376207zn2u3r u025r
24 Feb 23
FDA approves once-weekly ALTUVIIIOâ„¢, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection
5:20pm
IRAN
gsmfsah jxojg3
24 Feb 23
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
10:56am
6-K
3ky 72tcv53h62yuodc
21 Feb 23
Sanofi announces change in R&D leadership
12:52pm
SC 13G/A
s9llog8s47k4ukcvpmh
14 Feb 23
Sanofi / DODGE & COX ownership change
2:22pm